TiGenix hires Marie Paule Richard and Mary Carmen Diez ahead of Cx601 launch

Belgian cell therapy company TiGenix (Euronext Brussels: EBR) has appointed Marie Paule Richard as chief medical officer, and Mary Carmen Diez as its vice president of medical affairs and new product commercialization.

Dr Richard has previously held the same position at Aicuris in Germany, as well as high-level medical officer positions at Crucell in Switzerland and France’s Sanofi Pasteur, leading development and regulatory approval of several products in Europe and the USA. At TiGenix, she will head the development of Cx611 in early rheumatoid arthritis and severe sepsis, as well as completing ongoing European Phase III studies for Cx601 in Crohn’s disease, and its preparation of an American developmental plan for the drug.

Dr Diez has more than 20 years’ experience in the biopharma industry, and joins TiGenix from Meda Pharma, where she was an international medical marketing director for nine years, during which time she launched several products in Europe. She has also worked at Asta Medica, Pfizer and Dupont. She will now be responsible for preparing the launch of Cx601 in Europe.